Abstract. During hepatic fibrogenesis, quiescent hepatic stellate cells (HSCs) undergo phenotypic transformation into activated matrix-producing cells. This process is recapitulated in primary HSCs cultured on plastic. Based on studies in rats, peroxisome proliferator-activated receptor Á (PPARÁ) has been suggested to play a key role in the control of HSC activation. Indeed, in rats, PPARÁ expression is depleted in activated HSCs. PPARÁ ligands inhibit HSC activation and prevent hepatic fibrosis in vivo. Here we evaluated the impact of PPARÁ agonists on hepatic fibrogenesis in mice both in vitro and in vivo. Primary HSCs from Balb/C mice were cultured with PPARÁ ligands Pioglitazone (PGZ) or 15-deoxy-Δ12,14 prostaglandin J 2 (15d-PGJ 2 ). PPARÁ mRNA expression was stable during culture-activation of HSCs. However, PPARÁ protein was only found in quiescent HSCs but not in fully activated cells. Exposure of HSCs to PPARÁ agonists maintained the expression of PPARÁ, and transactivated this transcription factor as demonstrated by gelshift assay and by induction of CD36, a PPARÁ-regulated gene. However, PPARÁ ligands did not alter the induction of Collagen-I mRNA or ·-smooth muscle actin (·-SMA) in cultured HSCs. To test the effect of PPARÁ agonist PGZ in vivo, hepatic fibrosis was evaluated in Balb/C or C57BL6/J mice treated with CCl 4 (three times a week for 4 weeks; or corn oil for controls), and fed a normal or a PGZ-supplemented diet (0.01% wt/wt). PGZ treatment was associated with increased serum adiponectin concentrations but did not decrease the severity of hepatic fibrosis induced by CCl 4 . Our data demonstrate that, although having anti-fibrotic properties in rats, PPARÁ agonists do not prevent activation of HSCs in vitro, nor hepatic fibrogenesis in vivo in mice.
Introduction
Liver fibrosis is the consequence of most types of chronic liver disease and results from excess deposition of extracellular matrix (ECM) components generated mainly by hepatic stellate cells (HSCs) (1, 2) . In the normal liver, HSCs play a key role in the storage and transport of vitamin A (3). In response to liver injury, or spontaneously when cultured on plastic, these cells activate or trans-differentiate into myofibroblasticlike cells, acquiring contractile, proliferative, pro-inflammatory and fibrogenic properties (4, 5) . Most of the anti-fibrotic treatments currently under evaluation aim at inhibiting the activation of HSCs (6, 7) . The identification of key cytokines, transcription factors and molecular mechanisms controlling HSC activation is believed to lead to pathophysiologicalbased strategies to treat liver fibrosis.
Peroxisome proliferator-activated receptor Á (PPARÁ), a member of the steroid/retinoid nuclear hormone receptor superfamily of ligand-activated transcription factors (8) , has been proposed as a potential molecular target for inhibition of HSC trans-differentiation. PPARÁ has been shown to be expressed in quiescent HSCs and its expression and activity decreased during HSC activation in vitro and in vivo in rats (6, 7, 9) . The treatment of rat HSCs with ligands for PPARÁ prevented their activation in vitro. In addition, forced expression of PPARÁ in culture-activated HSCs by means of adenoviral transfection has been shown to revert their phenotype to that of quiescent cells (10) (11) (12) .
In vivo, treatment of rats with thiazolidinediones drugs [Pioglitazone (PGZ) or rosiglitazone], which are synthetic ligands for PPARÁ, prevent hepatic fibrosis resulting from chronic toxic injury or bile duct ligation (6, 7, 13) . Despite this potent preventive effect, PGZ has limited efficacy in the treatment of pre-established hepatic fibrosis. Indeed, we recently published that PGZ halts the progression of hepatic fibrosis only when the treatment is administered early in the course of toxic or metabolic disease (14) .
PPARÁ activation plays a role in various physiological and pathophysiological events, including the stimulation of adipocyte differentiation, the response to insulin and the regulation of lipid metabolism as well as the maturation of monocyte/macrophages and the control of inflammatory reaction (15) . Therefore, besides direct action on HSCs, PPARÁ stimulation may also interfere with the fibrotic process via modulation of adipocytokine production or as a consequence of its anti-inflammatory properties. The use of genetically modified mice is therefore a good tool to explore the implication of such additional mechanisms for the antifibrotic effect of PPARÁ agonists. As a prerequisite to such studies, the anti-fibrotic properties of PPARÁ agonists need to be evaluated in mice.
Thus we analysed the regulation of PPARÁ expression during the culture activation of mouse primary HSCs as well as the impact of PPARÁ agonist on matrix production and HSC activation. We also examined the effect of treatment with the PPARÁ agonist PGZ on CCl 4 -induced hepatic fibrosis in mice in vivo. Surprisingly, and contrasting with observations in rats, PGZ did not prevent hepatic fibrosis in mice. Moreover, although we found PPARÁ to be expressed in quiescent HSCs and downregulated during their activation, PPARÁ agonists did not prevent collagen I expression nor myofibroblastic trans-differentiation in cultured murine HSCs.
Materials and methods
Animal studies. Female Balb/C and C57BL6/J mice, were obtained from Elevage Janvier (Le Genest Saint Isle, France). All animals were kept in a temperature-and humiditycontrolled environment in a 12-h light-dark cycle. They were allowed free access to water and food. The animals were handled according to the guidelines for humane care for laboratory animals established by the Université Catholique de Louvain (UCL), and the study protocol was approved by the local ethics committee. To examine the effect of Pioglitazone (PGZ) on hepatic fibrosis, 8-week-old Balb/C mice were randomly divided into 4 experimental groups (n=5 per group). Mice were injected with CCl 4 (400 μl/kg body weight in corn oil) intra-peritoneally three times a week for 4 weeks and fed a standard powdered diet (Pavan Service Carfil Quality, Oud-Thurnout, Belgium) (CCl 4 group) or a PGZ-supplemented diet (CCl 4 +PGZ group). The PGZsupplemented diet was prepared by mixing PGZ (Takeda Chemical Industries, Osaka, Japan) with the powdered standard diet to obtain a 0.01% Pioglitazone diet (wt/wt). As controls, mice received intra-peritoneal injections of corn oil (3 times/week for 4 weeks) and were fed a normal diet (control group) or the PGZ-supplemented diet (PGZ group). A similar experiment was repeated on the female C57BL6/J mice.
At the time of sacrifice (48 h after the last injection of CCl 4 ), blood was collected by cardiac puncture and the liver and abdominal subcutaneous fat rapidly excised. Part of the liver was fixed in 4% formalin, embedded in paraffin and used for histological analyses. The remaining liver and the subcutaneous adipose tissue were snap frozen in liquid nitrogen and kept at -80˚C until use.
Isolation and characterization of hepatic stellate cells.
Primary HSCs were isolated from female Balb/C mice by in situ pronase-collagenase digestion of the liver followed by density centrifugation on a Histodenz gradient (11%) as described by others (16) . Five mouse livers were perfused for each isolation. After isolation, the cells were re-suspended in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Merelbeke, Belgium) supplemented with 20% foetal bovine serum (FBS, Invitrogen), 100 units/ml penicillin and 100 μg/ ml streptomycin (Invitrogen). Primary HSCs were cultured in cell culture dishes at 37˚C in a humidified atmosphere with 5% CO 2 and 95% air. At day 1, the medium was removed and replaced by DMEM supplemented with 5% FBS.
The purity of the cultures was evaluated by examining the characteristic stellate shape of the cells with phase-contrast microscopy and by the presence of lipid droplets by autofluorescence using an excitation light of 320 nm. After the first replacement of medium (day 1), purity was >90%. At day 9 the cells were passaged by treatment with 5 ml of Trypsin-EDTA 0.5X (Invitrogen) per dish for 7 min at 37˚C. After addition of 5 ml of DMEM with 20% FBS, the cells were collected and washed twice in PBS, and seeded in DMEM supplemented with 5% FBS.
HSC treatment.
To analyse the effect of PPARÁ agonists on HSC biology, HSCs were incubated with DMEM supplemented with 5% FBS containing PGZ 10 μM (Takeda Chemical Industries), or vehicle (DMSO). In separate experiments, cells were incubated with the most potent PPARÁ activator 15-deoxy-Δ12,14 prostaglandin J 2 (15d-PGJ 2 ) 10 μM (Sigma Aldrich, ref. no. D8440, Bornem, Belgium) or vehicle (ethanol 0.5%). Treatment was initiated at day 1 or day 3 after plating as indicated in the Results section. Medium was renewed every 2 days and the cells were passaged at day 9.
Total RNA extraction. Total RNA was extracted from cultured HSCs or from liver or adipose tissue using the TriPure isolation reagent kit (Roche Diagnostics Belgium, Vilvoorde). cDNA was prepared by reverse transcription of 1 μg total hepatic RNA using random primers and M-MLV (Moloney murine leukemia virus) reverse transcriptase (Gibco BRL, Merelbeke, Belgium). To assess the expression of PPARÁ mRNA in HSCs during culture conditions, gene amplification was conducted using TaqDNA polymerase (Amersham Biosciences, Diegem, Belgium) and primers (sense, 5'-aagag atcacagagtatgcc-3' and anti-sense, 5'-cttcacagcaaactcaaac-3'). This expression was compared to that of Ribosomal protein L19 (RPL19) RNA (primers: sense, 5'-agtatgctcaggcttcagaa-3'; and anti-sense, 5'-gcaggtctaagaccaaggaa-3') serving as control (17) . The cycle conditions were 94˚C for 5 min, 94˚C for 1 min, 56˚C for 1 min and 72˚C for 1 min (30 cycles) and then 72˚C for 10 min.
To quantify gene expression, real-time PCR analysis was carried out with the GeneAmp 5700 sequence detection system and software (Applied Biosystems, Den Ijssel, Netherlands) using SYBR-Green for detection. RPL19 RNA was chosen as an invariant standard. Adiponectin, CD36, Collagen-·I (Col-·I), PPARÁ total and RPL19 primers were designed using the Primer Express design software (Applied Biosystems). The following primers were used: adiponectin: sense, 5'-gcagagatggcactcctgga-3' and anti-sense, 5'-cccttcag ctcctgtcattcc-3'; CD36: sense, 5'-tccagccaatgcctttgc-3' and anti-sense, 5'-ttctgcactgaaaaagtaatctcca-3'; Col-·I: sense, 5'-ttcacctacagcacgcttgt-3' and anti-sense, 5'-tcatcgaatacaaaacca ccaaga-3'; PPARÁ total: sense, 5'-ctgctcaagtatggtgtccatga-3' and anti-sense, 5'-tgaataaagatggagtcctcatctca-3'; and RPL19: sense, 5'-gaaggtcaaagggaatgtgttca-3' and anti-sense, 5'-acaagctgaaggcagacaagg-3'. cDNA derived from adipose tissue or the liver was used to prepare standard dilution curves. PCR reactions were performed according to the standardized thermal profile of the system previously set by the manufacturer. All tissue and standard curve samples were run in duplicate at the same time in a single 96-well reaction plate (MicroAmp Optical, Applied Biosystems) using the appropriate primers. Results are expressed as relative gene expression (RGE) using the ΔCt method (User bulletin 2, Applied Biosystems).
Histology, immunohistochemistry and immunocytochemistry. Mouse livers were fixed in 4% neutral buffered formalin overnight, processed to paraffin blocks, sectioned, and stained with hematoxylin and eosin or sirius red (to visualize collagen deposition) by using standard techniques. Immunodetection for ·-smooth muscle actin (·-SMA) was performed as previously described (18), using mouse monoclonal anti-·-SMA (Clone 1A4; 1:100) and the EnVision Dako mouse as secondary antibody. All reagents were from DakoCytomation (Via Real, USA), unless indicated otherwise.
For immunocytochemistry experiments, the cells were seeded on plastic Thermanox™ coverslips (25 mm in diameter, Nunc, Rochester, NY, USA). At determined times (ranging from 1 to 12 days) the coverslips were washed once in PBS and the cells were fixed by immersion in formaldehyde 4% at 4˚C for 5 min. Endogenous peroxidases were inhibited by incubating the coverslips in methanol with 0.1% H 2 O 2 . After immersion in PBS containing 10% normal goat serum for 20 min, the coverslips were incubated with either mouse monoclonal anti-·-SMA antibody (1:300) (Clone 1A4), mouse monoclonal anti-Desmin antibody (1:500) (Clone D33), rabbit polyclonal anti-GFAP antibody (1:1000) (Clone 6F2) or anti-PPARÁ antibody (1:50) (H-100; Santa-Cruz, Heidelberg, Germany) overnight at 4˚C. After washing in PBS, the coverslips were incubated with the appropriate peroxidaseconjugated secondary antibody at room temperature for 1 h. Peroxidase activity was revealed with 3-amino-9-ethylcarbazole (DakoCytomation). Slides were then counter-stained in haematoxylin and eosin and examined under the microscope. The percentage of positive cells was determined by counting the stained cells versus the total number of cells.
Preparation of cell lysates and nuclear extracts. Lysates for
Western blot analyses were obtained by incubating the cells in 500 μl of buffer containing 150 mM NaCl; 1.5 mM MgCl 2 ; 10% Glycerol; 0.1% Triton X-100; 1 mM EGTA; 50 mM HEPES and 2 μg/ml of aprotinin and of leupeptin; for 5 min at 37˚C. The resulting lysates were collected and clarified by centrifugation (10 min at 12,000 x g). Nuclear extracts were prepared using the nuclear extract kit (Active Motif, Rixensart, Belgium), and stored at -80˚C. The protein contents were determined using a BCA protein assay with serum albumin as a standard (Pierce Chemical, Rockford, IL, USA).
Western blotting. Proteins from HSC lysates were separated by SDS-PAGE and transferred onto PVDF transfer membranes (PolyScreen). Fifty-five micrograms of proteins were loaded for the detection of PPARÁ and ·-SMA.
Homogenates from adipose tissue were used as positive controls for PPARÁ Western blots. The membranes were then stripped (Pierce's restore Western blot stripping, Milwaukee, WI, USA) and reprobed with ß-actin antibody to assess equal protein load. The following antibodies and conditions were used: a rabbit polyclonal anti-PPARÁ antibody (H-100; Santa-Cruz, Heidelberg, Germany; 1:1000; overnight), a mouse monoclonal anti-·-SMA antibody (Clone 1A4, DakoCytomation, 1:5000; 1 h); a mouse monoclonal anti-ß-actin antibody (Clone AC-15, Sigma, Heidelberg, Germany; 1:80.000; 1 h); secondary peroxidase-conjugated AffiniPure goat anti-mouse or goat anti-rabbit antibodies (Jackson ImmunoResearch, Cambridgeshire, UK) for ß-actin and ·-SMA or PPARÁ, respectively. The antigen-antibody reaction was visualized using the Western lightning chemiluminescence reagent plus (PerkinElmer) detection system followed by exposure of the membranes to a Kodak X-Omat Blue XB film. The quantification of immune-reactive proteins was obtained by densitometry using the Gel Doc 2000 device and software (Bio-Rad, Nazareth, Belgium).
Electrophoretic mobility shift assays (EMSA).
Ten micrograms of nuclear proteins were incubated for 20 min on ice in binding buffer (Tris-HCl 10 mM pH 7.5, NaCl 50 mM, EDTA 1 mM, DTT 1 mM, glycerol 5%) containing 1 μg poly(dI-dC) (2 μg/μl) and 0.5 ng of Á-32P end-labelled double-stranded oligonucleotides (20.000 cpm). Nuclear extracts (5 μg) from COS-7 transfected with PPARÁ (Active Motif, Rixensart, Belgium) were used as positive control. DNA protein complexes were separated by electrophoresis (200 V, 2 h) on a 5% polyacrylamide gel (29:1 cross-linking) in a 1X TBE buffer (88 mmol/l TRIS, 88 mmol/l boric acid, 2 mmol/l EDTA). Gels were dried and exposed to a Kodak BioMax MS Film (Amersham International plc, Little Chalfont, UK) for 24 h. Pre-annealed chromatographypurified double-stranded oligonucleotides containing the peroxisome-proliferator-responsive element (PPRE) (5'-TGC ACATTTCACCCAGAGAGAAGGGATTGA-3') were used as a probe (7). To confirm the identity of the protein/DNA binding, a supershift analysis was performed as follows: NE were pre-incubated with 2 μl of specific antibody (2 μg/μl) (PPARÁ H-100; Santa-Cruz) for 20 min on ice. Then the binding buffer, dI-dC and probe were added and the mixture was incubated for a further 20 min on ice.
Biochemical assays. The level of adiponectin in serum was determined using a mouse adiponectin RIA kit (Linco Research, MO, USA). The hydroxyproline content was determined on liver samples hydrolyzed in 5 ml 6 M HCl at 110˚C for 18-24 h as previously reported (19) using hydroxyproline 40 μg/ml (Sigma Aldrich) as a standard.
Statistical analysis.
Results are expressed as mean ± standard deviation (SD). Statistical differences between groups were tested using one way analysis of variance (ANOVA). Statistical significance was assumed for p values <0.05.
Results

PPARÁ expression in cultured HSCs.
We evaluated the expression of PPARÁ in quiescent HSCs (day 3) and its regulation during activation of HSCs under culture conditions. Quiescent HSCs and HSCs cultured for up to 9 days expressed PPARÁ mRNA at similar levels (Fig. 1A) . After 12 days in culture (i.e. after one passage at day 9), we observed a decreased expression of PPARÁ mRNA (Fig. 1A) . The decreased expression of PPARÁ mRNA after long-term culture and passage has been confirmed by quantification of PPARÁ transcripts by real-time PCR (not shown). We then evaluated the expression of PPARÁ protein by Western blotting. The presence of PPARÁ protein was readily demonstrated in HSCs cultured for up to 5 days, but the protein was no longer detected in HSCs cultured for longer periods (6, 7 or 8 days) (Fig. 1B) . As demonstrated by ·-SMA expression, the loss of PPARÁ protein detection occurred when HSCs underwent activation into myofibroblasts. Thus, after 5 days in culture, there was a marked decrease in PPARÁ protein expression, while transcript expression was maintained for up to 9 days, suggesting that the inhibition of protein occurs first at the post-transcriptional then at the transcriptional level during the culture activation of HSCs.
Functionality of PPARÁ in cultured HSCs.
To assess whether the PPARÁ transcription factor is functionally active in HSCs, we analysed the mRNA expression of a PPARÁ-regulated gene, CD36, in cultured HSCs by real-time PCR. Primary HSCs have been cultured from day 1 to 7 in DMEM supplemented with PGZ 10 μM, or DMSO (vehicle) or in the presence of the potent PPARÁ ligand 15d-PGJ 2 10 μM, or ethanol 0.5% used as vehicle. The CD36 mRNA expression was increased in cells treated with PPARÁ agonists (Fig. 2A) , suggesting the functionality of PPARÁ in cultured HSCs. To confirm these results we performed EMSA using a typical peroxisome proliferator responsive element (PPRE) as target oligonucleotide. After 3 days in culture, HSCs were exposed for 2 h to PGZ (10 μM), 15d-PGJ 2 (10 μM) or vehicle (DMSO or ethanol, respectively). Nuclear proteins were then extracted and subjected to a gel shift assay. Nuclear extracts from PPARÁ-transfected COS-7 cells served as positive controls. As shown in Fig. 2B , a retarded band was observed in PGZ-compared to DMSO-treated HSCs. Similarly, the 
Effect of PPARÁ ligands on PPARÁ protein expression in cultured HSCs.
To evaluate the impact of PPARÁ ligand on PPARÁ protein expression in our culture system, murine primary HSCs were cultured with PGZ (10 μM), or vehicle 24 h after seeding. Lysates were prepared at day 3 and day 7, and used for Western blot analysis. At day 3, PPARÁ protein was expressed at similar intensity in HSCs whether cultured in the presence or in the absence of PGZ (Fig. 3) . At day 7, PPARÁ protein was not detected in control cells. However, culture of HSCs in the presence of PGZ was associated with the persistence of PPARÁ protein expression (Fig. 3) . This treatment did not affect the trans-differentiation of the cells as confirmed by the ·-SMA protein expression in the different groups of treated HSCs (Fig. 3) .
Effects of PPARÁ agonists on HSC activation.
To assess the effects of PPARÁ activation on fibrogenesis in vitro, we evaluated Collagen-I mRNA expression by real-time PCR in HSCs cultured for 4 days in the presence of PGZ (10 μM) or 15d-PGJ 2 (10 μM). As shown in Fig. 4A and B, treatment with PGZ or 15d-PGJ 2 from day 3-7 did not affect the expression of Collagen-I mRNA, relative to vehicle-treated cells. Similarly, no change in Collagen-I mRNA was seen in HSCs exposed to PPARÁ ligands as early as 24 h after seeding (from day 1-5).
As expected, the proportion of HSCs expressing ·-SMA increased progressively with time in culture so that 22 and 76% of HSCs were ·-SMA positive at day 3 and 7, respectively. To evaluate the impact of PGZ treatment on HSC activation, we incubated the cells with PGZ (10 μM) or DMSO 24 h after plating and evaluated the number of ·-SMA expressing cells at day 3 and day 7. As shown in Fig. 4C , the percentage of HSCs expressing the ·-SMA protein was similar in the PGZ and the DMSO-treated HSCs, demonstrating that PGZ does not prevent the spontaneous activation of murine HSCs in culture.
Effect of PPARÁ agonist PGZ on hepatic fibrogenesis in vivo.
To determine whether PGZ has anti-fibrotic properties in vivo in mice, we induced hepatic fibrosis in female Balb/C or *** p<0.001 compared to 2-day-old, untreated HSC. There is no significant difference between PGZ-and DMSO-treated cells, nor between 15d-PGJ 2 -and ethanol-treated HSC. C57BL6/J mice by repeated intra-peritoneal injections of CCl 4 for 4 weeks. During this period, mice were fed a PGZsupplemented diet (0.01% wt/wt) (n=5) or a standard mouse chow (n=5). Mice fed a PGZ-supplemented diet or a standard chow and injected with corn oil served as non-fibrotic controls.
In CCl 4 -Balb/C mice, treatment with PGZ induced a 3-fold induction of adiponectin mRNA expression in adipose tissue (4.39±2.21 versus 1.19±0.7 arbitrary units in controls; p=0.03). This was paralleled by a 3-fold increase in serum adiponectin in PGZ-treated versus untreated CCl 4 -Balb/C mice (Fig. 5) . Administration of CCl 4 to Balb/C mice induced liver fibrosis with formation of collagen bridges between central veins (Fig. 6A) . PGZ treatment did not significantly alter the severity of fibrosis induced by CCl 4 as demonstrated by Sirius red staining (Fig. 6B) . Moreover, the amount and distribution of activated HSCs expressing ·-SMA were not different whether CCl 4 -Balb/C mice were treated or not with PGZ ( Fig. 6C and D) . In keeping with the histological findings, hepatic hydroxyproline content (Fig. 6E) and induction of hepatic Collagen-I mRNA (Fig. 6F) were at least as high in PGZ-treated than in untreated CCl 4 -Balb/C mice.
To ensure that this absence of anti-fibrotic effect was not strain-dependent, we repeated the experiment on C57BL6/J mice. As in the Balb/C mice, PGZ treatment of the C57BL6/J mice induced the expression of adiponectin transcripts in adipose tissue (not shown) and circulating levels of adiponectin (Fig. 5) . As reported by others (20) , a similar CCl 4 regimen resulted in liver fibrosis of a lesser severity in C57LB6/J than in Balb/C mice demonstrated by peri-centrolobular fibrosis with incomplete bridges (not shown), lower hepatic hydroxyproline content (Fig. 6E ) and lower levels of hepatic Collagen-I mRNA (Fig. 6F) . Thus, as observed in Balb/C mice, PGZ treatment did not reduce the severity of CCl 4 -induced fibrosis in C57BL6/J mice.
Discussion
The thiazolidinediones (TZDs), a new class of insulin sensitising anti-hyperglycemic agents, have been identified as high-affinity ligands for PPARÁ, a nuclear hormone receptor that plays a central role as a regulator of terminal adipocyte differentiation (21) . It has been shown that, in rats, TZDs significantly reduce the severity of hepatic fibrosis (7). This raises the possibility that TZDs may be used for the prevention and treatment of hepatic fibrosis, and as drugs of particular interest for fibrosis associated with the metabolic syndrome or non-alcoholic steatohepatitis.
Based on their studies of rat HSCs, Tsukamoto and group have proposed the concept that PPARÁ is a key regulator of HSC biology, maintaining HSCs in their quiescent phenotype (10) . In accordance with observations in rat cells (9), we found PPARÁ protein to be expressed in quiescent primary HSCs of mouse origin. Exposure of these cells to PPARÁ agonist PGZ activated the transcription factor as demonstrated by the induction of the PPARÁ/PPRE binding complex by EMSA as well as by induced expression of CD36, a PPARÁ-regulated gene. As in rat cells, cultured-activation of mouse HSCs was associated with a decreased expression of PPARÁ, and their treatment with PPARÁ ligand prevented the reduction in PPARÁ protein expression during cultureinduced activation. Despite the presence of functional and ligand-responsive PPARÁ, the activation of this transcription factor failed to prevent, or even attenuate, the activation of mouse HSCs in vitro, as it did in rat cells (7, 9) . Indeed, induction of Collagen-I mRNA and of ·-SMA during culture was not modified by exposure of the cells to PPARÁ ligands PGZ or 15d-PGJ 2 .
In rats, two specific mechanisms have been proposed to explain the anti-fibrotic effect of PPARÁ agonists. The first one is based on the observations that PPARÁ expression is lost in activated HSCs and that forced expression of PPARÁ by mean of viral transfection is sufficient to revert HSCs to their quiescent phenotype. By analogy to the adipogenic role of PPARÁ on adipocytes, this transcription factor might thus be necessary for HSCs to retain their 'adipogenic' phenotype, which is characterized by their ability to concentrate vitamin A in lipid droplets and by their quiescence in terms of the proliferation and production of extracellular matrix. The second mechanism involves the direct participation of PPARÁ in the transcriptional regulation of genes specific to fibrogenesis. In a recent study, Yavrom et al showed that, although no PPRE sequence was found in the promoter of the rat Collagen-I gene, PPARÁ suppresses the proximal Collagen-I promoter via inhibition of p300-facilitated NF-I binding to DNA in rat HSCs (22) . Our observations firmly demonstrated that ligand stimulation of PPARÁ in mice HSCs, although having transcriptional activity, did not act as a molecular switch to prevent spontaneous activation of the cells during culture on plastic. Moreover, this transcription factor did not appear to participate in the transcriptional control of the Collagen-I gene involved in fibrogenesis. Promoter analysis will be needed to confirm this.
We show here, in two different strains of mice, that PPARÁ agonist PGZ did not exert anti-fibrotic properties in mice in vivo. Indeed, PGZ had no impact on hepatic fibrosis, induction of hepatic Collagen-I gene expression or activation of hepatic stellate cells induced by chronic administration of CCl 4 . This is in sharp contrast with several reports on the anti-fibrotic properties of PPARÁ agonist drugs in various models of fibrosis in rats (6, 7, 13) . In the literature, this antifibrotic effect has been related to inhibition of HSC activation (7, 9, 13) . Therefore, if direct regulation of HSC biology is the principal mechanism implicated in the antifibrotic effect of PPARÁ agonists in rats, the absence of preventive effect of PGZ on hepatic fibrosis in vivo in mice is not surprising in light of our in vitro results.
A common observation in all studies published to date is that TZD treatment induces the expression of an adipocytespecific secretory protein, adiponectin (23) . Adiponectin has anti-fibrotic properties. Mice lacking adiponectin are exquisitely sensitive to hepatic fibrosis while supraphysiological levels of adiponectin induced by adenovirus infection prevent CCl 4 -induced fibrosis in wild-type mice (24) . In our study, as in similar studies in mice (23, 25) , PGZ administered as a food mixture increased the expression of adiponectin mRNA in adipose tissue as well as serum levels of adiponectin by a factor 2 to 3. Despite this, PGZ did not protect against fibrosis. This suggests that the rise in adiponectin levels, as obtained by PGZ treatment, is insufficient to provide protection against hepatic fibrosis. Unfortunately, the increase of PGZ doses above the therapeutic range used in this study does not further increase adiponectin levels (25) . Alternatively, as PPARÁ regulates many functions in adipocytes (24) , as well as in inflammatory cells (26, 27) , the fibro-protective properties of adiponectin may be counterbalanced by the fibro-permissive effect of other factors regulated by PPARÁ.
In summary, ligand activation of PPARÁ by PGZ does not prevent hepatic fibrogenesis in mice. This is related to the fact that the transcription factor does not control the activation of murine HSCs nor the transcription of fibrogenic genes such as Collagen-I. In addition, the modulation of the production of adiponectin by therapeutic doses of PGZ has a negligible impact on hepatic fibrogenesis.
